Dee Dragon - Senti Biosciences Vice Culture
| SNTI Stock | USD 2.17 0.05 2.36% |
Executive
Dee Dragon is Vice Culture of Senti Biosciences
| Address | 2 Corporate Drive, South San Francisco, CA, United States, 94080 |
| Phone | 650 239 2030 |
| Web | https://www.sentibio.com |
Senti Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3302) % which means that it has lost $0.3302 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1107) %, meaning that it created substantial loss on money invested by shareholders. Senti Biosciences' management efficiency ratios could be used to measure how well Senti Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.82. The current Return On Capital Employed is estimated to decrease to -0.91. As of now, Senti Biosciences' Net Tangible Assets are increasing as compared to previous years. The Senti Biosciences' current Non Currrent Assets Other is estimated to increase to about 2.1 M, while Total Assets are projected to decrease to under 105.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Alan CPA | Tyra Biosciences | 67 | |
| Raul MD | Cingulate | 66 | |
| Ali JD | Tyra Biosciences | N/A | |
| Paul Kassner | RAPT Therapeutics | 57 | |
| Michael Listgarten | RAPT Therapeutics | N/A | |
| Michael JD | Foghorn Therapeutics | 59 | |
| Katie Johnston | Lipella Pharmaceuticals Common | N/A | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Alfonso MD | Foghorn Therapeutics | 53 | |
| Sarah Honig | Tyra Biosciences | N/A | |
| Mark Conley | SAB Biotherapeutics | N/A | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| Kevin Brennan | Xilio Development | 54 | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Liz Pagano | Tyra Biosciences | N/A | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| Robert Andrade | Fennec Pharmaceuticals | 49 | |
| Christiana MBA | Fennec Pharmaceuticals | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Julissa Viana | Xilio Development | N/A | |
Management Performance
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.33 |
Senti Biosciences Leadership Team
Elected by the shareholders, the Senti Biosciences' board of directors comprises two types of representatives: Senti Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Senti. The board's role is to monitor Senti Biosciences' management team and ensure that shareholders' interests are well served. Senti Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Senti Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dee Dragon, Vice Culture | ||
| Thomas Chung, Vice Development | ||
| Susan Kahlert, Controller | ||
| Kanya MD, Head President | ||
| Yvonne MBA, Treasurer CFO | ||
| James Collins, Chairperson CoFounder | ||
| Wilson Wong, Scientific Board | ||
| Deborah Knobelman, CFO Treasurer | ||
| Philip Lee, CoFounder CTO | ||
| Susan Berland, Senior Director | ||
| Mike Rhee, General Secretary |
Senti Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Senti Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (180.17) % | ||||
| Current Valuation | 34.19 M | ||||
| Shares Outstanding | 4.59 M | ||||
| Shares Owned By Insiders | 21.00 % | ||||
| Shares Owned By Institutions | 23.32 % | ||||
| Number Of Shares Shorted | 65.09 K | ||||
| Price To Book | 0.62 X | ||||
| Price To Sales | 29.47 X |
Currently Active Assets on Macroaxis
When determining whether Senti Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Senti Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Senti Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Senti Biosciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Senti Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.59) | Revenue Per Share 0.075 | Quarterly Revenue Growth (1.00) | Return On Assets (0.33) | Return On Equity (1.11) |
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Senti Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.